PubMed Health⌕ Search

PubMed · 12458411

Comparison of methods for particulate phase mercury analysis: sampling and analysis.

Abstract

Accurate and reliable sampling and analysis of mercury forms is an overriding aim of any atmospheric monitoring effort which seeks to understand the fate and transport of the metal in the environment. Although a fraction of the total mercury forms found in the atmosphere, particulate phase mercury, Hg(p), is believed to play a prominent role in both wet and dry deposition to the terrestrial and aquatic environments. Currently, microwave acid extraction and thermoreductive methodologies for analysis of Hg(p) samples are widely used. We report on the potential for the use of a thermoreductive method for Hg(p) analysis to evaluate and optimize it for use in routine monitoring networks. Pre-baked quartz filters can be placed in particulate samplers with well-characterized size cuts, such as dichotomous samplers and microoriface impactors. The thermoreductive methodology facilitates rapid analysis after sample collection. It requires no chemical extraction thereby eliminating the potential for contamination and generation of hazardous waste. Our results indicate that, on average, the thermoreductive method yields 30% lower values for fine fraction Hg(p) when compared with microwave acid digestion. This may be due to matrix interferents that reduce the collection efficiency of mercury onto gold preconcentration traps. Results for total particulate mercury samples indicate that on average the thermoreductive method yields 56% lower values for the coarse fraction when compared with microwave acid digestion. Experiments were also conducted in Detroit, MI, USA to investigate whether elevated reactive gaseous mercury (Hg(2+)(g)) in an urban environment can lead to an artifact during the collection of filters for Hg(p) analysis. Our results indicate a significantly higher amount of Hg(p) collected onto a filter using the conventional methodology as compared to a filter collected downstream of KCl-coated annular denuders in the absence of Hg(2+)(g). These results point to the presence of Hg(2+)(g) as an artifact during Hg(p) measurement. These results indicate that a denuder must be utilized upstream of a filter for Hg(p) collection to prevent significant Hg(2+)(g) artifact formation.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Mary M Lynam, Gerald J Keeler. 2002-10-24. Comparison of methods for particulate phase mercury analysis: sampling and analysis.. https://doi.org/10.1007/s00216-002-1584-4

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗